The Cooperative is a new and innovative pharmacy benefit program that delivers cost savings to self-funded districts. Budgets are tight. Student achievement is our priority. This is a way to save money and put it back where it belongs, back to student achievement. This program is a win for your district and for advancing student success. With over 400,000 individuals enrolled, the School Rx program allows its members to take advantage of discounted pharmaceutical pricing.
Pharmacy benefits are currently unregulated and big insurance and pharmacy drug companies are able to hide revenue in complicated contract language. Self-insured school districts spend millions of dollars on pharmacy benefits and that number is expected to grow drastically. The NSBA School RX Cooperative offers the best of Pharmacy Benefit Management (PBM) thru Express Scripts with a watch dog component that is focused on helping school districts keep dollars in their pockets. Our program provides significant and guaranteed improvement in all areas of drug cost management. This includes discounts, dispensing fees, rebates and increased generic utilization. The NSBA School Rx Cooperative offers schools the ability to take advantage of national purchasing power to drive the best possible pricing and contract terms.
Have questions? Visit these helpful links:
Visit the Learn How to Save page to get further information on the
Cooperative and a free cost savings analysis.
- Health care costs have been consistently outpacing overall inflation in the past 10 years
- Prescription drug costs have skyrocketed during this time (to a point where employers are starting to question whether or not they can continue to offer this benefit to their employees)
- 5% of the employees covered by a prescription drug plan are incurring 80% of the employer’s cost
- Specialty medications in the top three therapy classes (inflammatory conditions, multiple sclerosis and cancer) increased 4% (cumulatively) from 2014 to 2015 (Express Scripts 2015 Drug Trend Report)
- Employers continue to increase copays and coinsurance, but that isn’t going to be a practical solution to managing this benefit when the cost of some drugs exceed $100,000 per year per person